Topics

Companies Related to "genomics profiling help identify best treatment bladder cancer" [Most Relevant Company Matches] RSS

13:30 EDT 18th July 2019 | BioPortfolio

Here are the most relevant search results for "genomics profiling help identify best treatment bladder cancer" found in our extensive corporate database of over 50,000 company records.

Showing "genomics profiling help identify best treatment bladder cancer" Companies 1–25 of 6,000+

Extremely Relevant

Bladder Cancer Advocacy Network

The Bladder Cancer Advocacy Network (BCAN - pronounced beacon) is the first national advocacy organization dedicated to improving public awareness of bladder cancer, advancing bladder cancer research and providing information and support to people affected by bladder cancer. Founded in May 2005, BCAN is a cooperative effort among bladder cancer survivors, their loved ones and the medical community...


Relevant

Onconome, Inc.

Onconome is dedicated to the discovery, development and commercialization of innovative biomarkers for the early and accurate detection of prostate, colon, bladder and other forms of cancer, including lung, breast, liver, pancreatic and stomach. Early detection is the key to successful treatment. Our serum tests for early detection of prostate and colon cancer and our urine test for bladder cancer...

Azign Bioscience A/S

Azign is a drug profiling and-discovery company. Azign combines pharmacological knowledge with expertise in functional genomics, post-genomics technologies and bioinformatics. Azign uses proprietary drug profiling techniques to predict therapeutic effects of compounds and discover and validate new drug targets either in-house or though partnerships. Azign is a leading developer of technologies for...


Clinical Genomics Pty Ltd

Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, lnSure® ONE™, a one sample fecal immunochemical test (FIT) for healthy adults to detect lower GI bleeding, and COLVERA®, a proprietary liquid biopsy blood test ...

TARIS Biomedical LLC

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www...

Sagres Discovery

Sagres Discovery is building a market position in oncology by applying innovative technologies to establish strong proprietary programs in oncogene discovery, molecular profiling, drug target validation, and therapeutic development.According to the National Institutes of Health, annual costs related to cancer in the U.S. totaled $156.7 billion in 2001. Worldwide cancer mortality is estimated to be...

Bristol-Myers Squibb and TARIS Biomedical LLC

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new therapies for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www....

Contextual Genomics Inc.

Contextual Genomics (www.contextualgenomics.com) has developed cost-effective and clinically actionable molecular tests that guide diagnosis and treatment of cancer. These customized tests are designed to be offered by partner laboratories around the world with Contextual conducting bioinformatics services via a SaaS model. The collection of data via this ...

Genomic Health

Genomic Health gives cancer patients and physicians insight needed to help make quality treatment decisions. GenomicHealth.com is designed to help patients, caregivers and healthcare professionals understand how individualized genomic profiling of tumor tissue may help improve cancer management. The first diagnostic assay developed by Genomic Health — Oncotype DX™ — is a breast cancer test t...

Rainier Therapeutics, Inc.

Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic and early stage bladder cancer, an area of high unmet need. The company’s antibody, vofatamab (B-701) is focused specifically on the fibroblast growth factor receptor 3 (FGFR3), a known driver of...

Sesen Bio, Inc.

Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company’s Targeted Protein Therapeutics platform. The company’s lead program, Vicinium™, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment ...

Contextual Genomics

Contextual Genomics believes that DNA analysis significantly improves human health and that geography should not be a barrier to the benefits of using molecular information to guide patient decisions. The company’s first products are actionable molecular tests that guide diagnosis and treatment of cancer and cardiovascular disease.

AKESOgen, Inc.

AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract r...

IMPATH

IMPATH is in the business of improving outcomes for cancer patients. With a database of over 870,000 patient profiles, IMPATH uses sophisticated technologies to provide patient-specific diagnostic, prognostic and treatment information to more than 8,300 physicians specializing in the treatment of cancer patients, in over 2,000 hospitals and over 570 oncology practices. Utilizing its comprehensive ...

IMPATH-BCP

IMPATH is in the business of improving outcomes for cancer patients. With a database of over 870,000 patient profiles, IMPATH uses sophisticated technologies to provide patient-specific diagnostic, prognostic and treatment information to more than 8,300 physicians specializing in the treatment of cancer patients, in over 2,000 hospitals and over 570 oncology practices. Utilizing its comprehensive ...

TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...

Agendia B.V.

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatment within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer therapy. The company markets four products, with several new genomic tests in development. ...

Genomics Institute of the Novartis Research Foundation

The Genomics Institute of the Novartis Research Foundation (GNF) has integrated state of the art technologies, making possible new approaches to complex biomedical problems in the neurosciences, immunology and cancer biology. These technologies cut across the life sciences and include genomics and proteomics tools, combinatorial chemistry, structural genomics and computational biology. The mission...

Telormedix SA

Telormedix (www.telormedix.com), founded in October 2007, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The Company’s lead product, TMX-101, recently entered a Phase I/II clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). ...

Viventia Biotech Inc

Viventia Biotech Inc. is a biopharmaceutical company advancing a new generation of monoclonal antibody therapeutics designed to offer safer, more beneficial therapies for cancer patients. Viventia’s lead product candidate Proxinium™ continues on an aggressive clinical development schedule. Viventia has initiated a Phase II North American clinical trial and concurrently commenced a pivotal Phas...

Orion Genomics.

Orion Genomics develops oncology diagnostic products for cancer screening and therapy selection. We leverage our suite of proprietary technologies to find and interpret normal and abnormal epigenetic patterns of DNA methylation, also known as DNA's Second Code.We are currently identifying epigenetic biomarkers and employing them in the development of novel molecular diagnostic tests to find breast...

Selah Genomics

Headquartered in Greenville, South Carolina, Selah Genomics has a singular focus on advancing more precise, personalized medicine services. We offer cutting edge genetic testing to better diagnose and monitor disease, detect risk, and identify which therapies will work best for individual patients, thereby improving patient outcomes.

Foundation Medicine, Inc.

Foundation Medicine is dedicated to the development of comprehensive tests that will help physicians personalize cancer treatment for their patients. Foundation Medicine’s laboratory tests are designed to accommodate and assimilate a dynamic landscape of cancer genome and other molecular information and growing availability of treatment options. These...

Cancer Treatment Centers of America at Eastern Regional Medical Center

Cancer Treatment Centers of America (CTCA) is a national network of hospitals providing a comprehensive, fully integrative approach to cancer treatment. CTCA serves patients with advanced cancer from all 50 states at facilities located in suburban Chicago, Philadelphia, Tulsa and suburban Phoenix. For more information about Cancer Treatment Centers of America, go to cancercenter.com.

Cancer Treatment Centers of America, Inc.

Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Stand...


More From BioPortfolio on "genomics profiling help identify best treatment bladder cancer"

Quick Search

Corporate Database Quicklinks